Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

  • 1

    KnightKWadeSBalducciL. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med2004;116(Suppl 7A):11S26S.

    • Search Google Scholar
    • Export Citation
  • 2

    SchwartzRN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm2007;64:S513; quiz S28–30.

    • Search Google Scholar
    • Export Citation
  • 3

    SteensmaDP. Is anemia of cancer different from chemotherapy-induced anemia?J Clin Oncol2008;26:10221024.

  • 4

    WilsonJYaoGLRafteryJ. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess2007;11:1202iii–iv.

    • Search Google Scholar
    • Export Citation
  • 5

    MoulletISallesGKettererN. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol1998;9:11091115.

  • 6

    LudwigHVan BelleSBarrett-LeeP. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer2004;40:22932306.

    • Search Google Scholar
    • Export Citation
  • 7

    GroopmanJEItriLM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst1999;91:16161634.

  • 8

    JefferiesSRajanBAshleyS. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol1998;48:2327.

  • 9

    GlausACrowRHammondS. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer1996;4:8296.

    • Search Google Scholar
    • Export Citation
  • 10

    MillerYBachowskiGBenjaminR. Practice guidelines for blood transfusion: a compilation from recent peer-reviewed literature2nd edition. Washington, DC; American Red Cross; 2007. Available at: http://www.redcross.org/www-files/Documents/WorkingWiththeRedCross/practiceguidelinesforbloodtrans.pdf. Accessed April 1 2012.

    • Search Google Scholar
    • Export Citation
  • 11

    WiesenARHospenthalDRByrdJC. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med1994;121:278230.

    • Search Google Scholar
    • Export Citation
  • 12

    KaderASLimJTBertheletE. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol2007;30:492497.

    • Search Google Scholar
    • Export Citation
  • 13

    SpivakJLGasconPLudwigH. Anemia management in oncology and hematology. Oncologist2009;14(Suppl 1):4356.

  • 14

    HillSRCarlessPAHenryDA. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev2002:CD002042.

    • Search Google Scholar
    • Export Citation
  • 15

    BlajchmanMAVamvakasEC. The continuing risk of transfusion-transmitted infections. N Engl J Med2006;355:13031305.

  • 16

    KingKEShireyRSThomanSK. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion2004;44:2529.

    • Search Google Scholar
    • Export Citation
  • 17

    YazerMHPodloskyLClarkeGNahirniakSM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion2004;44:1015.

    • Search Google Scholar
    • Export Citation
  • 18

    KhoranaAAFrancisCWBlumbergN. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med2008;168:23772381.

    • Search Google Scholar
    • Export Citation
  • 19

    JabbourEKantarjianHMKollerCTaherA. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer2008;112:10891095.

    • Search Google Scholar
    • Export Citation
  • 20

    VekemanFBookhartBKWhiteJ. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion2009;49:895902.

    • Search Google Scholar
    • Export Citation
  • 21

    PawsonRBrunskillSMurphyMF. Different threshold levels for red blood cell transfusions in patients with haematological malignancy (Protocol). Cochrane Database Syst Rev2006;3:CD006166.

    • Search Google Scholar
    • Export Citation
  • 22

    HebertPCWellsGBlajchmanMA. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med1999;340:409417.

    • Search Google Scholar
    • Export Citation
  • 23

    SteinbrookR. Erythropoietin, the FDA, and oncology. N Engl J Med2007;356:24482451.

  • 24

    LittlewoodTJBajettaENortierJW. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol2001;19:28652874.

    • Search Google Scholar
    • Export Citation
  • 25

    VansteenkisteJPirkerRMassutiB. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst2002;94:12111220.

    • Search Google Scholar
    • Export Citation
  • 26

    BohliusJWilsonJSeidenfeldJ. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst2006;98:708714.

    • Search Google Scholar
    • Export Citation
  • 27

    Food and Drug Administration. Epoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234Orig1s5266lbl.pdf. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 28

    Food and Drug Administration. Darbepoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s5258lbl.pdf. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 29

    UntchMFaschingPABauerfeindI. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 517.

    • Search Google Scholar
    • Export Citation
  • 30

    HedenusMAdrianssonMSan MiguelJ. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol2003;122:394403.

    • Search Google Scholar
    • Export Citation
  • 31

    HenkeMLaszigRRubeC. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet2003;362:12551260.

    • Search Google Scholar
    • Export Citation
  • 32

    Leyland-JonesBSemiglazovVPawlickiM. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol2005;23:59605972.

    • Search Google Scholar
    • Export Citation
  • 33

    OvergaardJHoffCMHansenHS. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): final outcome of the DAHANCA 10 trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 6007.

    • Search Google Scholar
    • Export Citation
  • 34

    SmithREJrAaproMSLudwigH. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol2008;26:10401050.

    • Search Google Scholar
    • Export Citation
  • 35

    ThomasGAliSHoebersFJ. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol2008;108:317325.

    • Search Google Scholar
    • Export Citation
  • 36

    WrightJRUngYCJulianJA. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol2007;25:10271032.

    • Search Google Scholar
    • Export Citation
  • 37

    BennettCLSilverSMDjulbegovicB. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299:914924.

    • Search Google Scholar
    • Export Citation
  • 38

    BohliusJSchmidlinKBrillantC. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet2009;373:15321542.

    • Search Google Scholar
    • Export Citation
  • 39

    TonelliMHemmelgarnBReimanT. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ2009;180:E6271.

    • Search Google Scholar
    • Export Citation
  • 40

    BennettCLHenkeMLaiSY. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia - reply. JAMA2008;300:28552857.

    • Search Google Scholar
    • Export Citation
  • 41

    LudwigHCrawfordJOsterborgA. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol2009;27:28382847.

    • Search Google Scholar
    • Export Citation
  • 42

    GlaspyJCrawfordJVansteenkisteJ. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer2010;102:301315.

    • Search Google Scholar
    • Export Citation
  • 43

    EngertAJostingAHaverkampH. Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol2010;28:22392245.

    • Search Google Scholar
    • Export Citation
  • 44

    MoebusVJackischCLueckHJ. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol2010;28:28742880.

    • Search Google Scholar
    • Export Citation
  • 45

    UntchMFaschingPAKonecnyGE. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: results at the time of surgery. Ann Oncol2011;22:19881998.

    • Search Google Scholar
    • Export Citation
  • 46

    PirkerRRamlauRASchuetteW. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol2008;26:23422349.

    • Search Google Scholar
    • Export Citation
  • 47

    GroteTYeildingALCastilloR. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol2005;23:93779386.

    • Search Google Scholar
    • Export Citation
  • 48

    HeitJASilversteinMDMohrDN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med2000;160:809815.

    • Search Google Scholar
    • Export Citation
  • 49

    KhoranaAAFrancisCWCulakovaE. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost2007;5:632634.

    • Search Google Scholar
    • Export Citation
  • 50

    LevineMNGentMHirshJ. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med1988;318:404407.

    • Search Google Scholar
    • Export Citation
  • 51

    SaphnerTTormeyDCGrayR. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol1991;9:286294.

    • Search Google Scholar
    • Export Citation
  • 52

    LymanGHKhoranaAAFalangaA. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol2007;25:54905505.

    • Search Google Scholar
    • Export Citation
  • 53

    GlaspyJOsterborgALudwigH. Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin [abstract]. Eur J Cancer Suppl2007;5:Abstract 147.

    • Search Google Scholar
    • Export Citation
  • 54

    PfefferMABurdmannEAChenCY. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med2009;361:20192032.

    • Search Google Scholar
    • Export Citation
  • 55

    Food and Drug Administration. FDA information on ESAs. 2010. Available at: http://www.fda.gov/cder/drug/infopage/RHE/. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 56

    BennettCLCournoyerDCarsonKR. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood2005;106:33433347.

    • Search Google Scholar
    • Export Citation
  • 57

    BennettCLLuminariSNissensonAR. Pure red-cell aplasia and epoetin therapy. N Engl J Med2004;351:14031408.

  • 58

    McKoyJMStonecashRECournoyerD. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion2008;48:17541762.

    • Search Google Scholar
    • Export Citation
  • 59

    Food and Drug Administration. FDA on ESA-associated PRCA. 2006. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=430. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 60

    BennettCLBeckerPSKrautEH. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial2009;22:14.

    • Search Google Scholar
    • Export Citation
  • 61

    BallenKKBeckerPSYeapBY. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol2004;22:40874094.

    • Search Google Scholar
    • Export Citation
  • 62

    BallenKKFordPAWaitkusH. Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplant2000;26:227229.

    • Search Google Scholar
    • Export Citation
  • 63

    BrownNMKimSYFordPA. Autologous stem cell transplants in Jehovah’s Witnesses. Bone Marrow Transplant2009;44:391392.

  • 64

    GlaspyJBukowskiRSteinbergD. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol1997;15:12181234.

    • Search Google Scholar
    • Export Citation
  • 65

    GabriloveJLCleelandCSLivingstonRB. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol2001;19:28752882.

    • Search Google Scholar
    • Export Citation
  • 66

    HenryDHGordanLNCharuV. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin2006;22:14031413.

    • Search Google Scholar
    • Export Citation
  • 67

    SteensmaDPMolinaRSloanJA. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol2006;24:10791089.

    • Search Google Scholar
    • Export Citation
  • 68

    CanonJLVansteenkisteJBodokyG. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst2006;98:273284.

    • Search Google Scholar
    • Export Citation
  • 69

    ThamesWASmithSLScheifeleAC. Evaluation of the US Oncology Network’s recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy2004;24:313323.

    • Search Google Scholar
    • Export Citation
  • 70

    BocciaRMalikIARajaV. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist2006;11:409417.

    • Search Google Scholar
    • Export Citation
  • 71

    HenryDH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO?Oncologist1998;3:275278.

  • 72

    WeissGGoodnoughLT. Anemia of chronic disease. N Engl J Med2005;352:10111023.

  • 73

    SilversteinSBGilreathJARodgersGM. Intravenous iron therapy: a summary of treatment options and review of guidelines. J Pharm Pract2008;21:431443.

    • Search Google Scholar
    • Export Citation
  • 74

    AuerbachMBallardHTroutJR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol2004;22:13011307.

    • Search Google Scholar
    • Export Citation
  • 75

    BastitLVandebroekAAltintasS. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol2008;26:16111618.

    • Search Google Scholar
    • Export Citation
  • 76

    HedenusMBirgegardGNasmanP. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007;21:627632.

    • Search Google Scholar
    • Export Citation
  • 77

    HenryDHDahlNVAuerbachM. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist2007;12:231242.

    • Search Google Scholar
    • Export Citation
  • 78

    PedrazzoliPFarrisADel PreteS. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol2008;26:16191625.

    • Search Google Scholar
    • Export Citation
  • 79

    SteensmaDPSloanJADakhilSR. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol2011;29:97105.

    • Search Google Scholar
    • Export Citation
  • 80

    MhaskarRWaoHKumarA. Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: a systematic review and meta-analysis [abstract]. Blood2010;116(Suppl 21):Abstract 2055.

    • Search Google Scholar
    • Export Citation
  • 81

    National Institutes of Health. Ferrlecit package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f2f298-2dec-4020-97c8-2aade4b99b2e. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 82

    National Institutes of Health. Venofer package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a. Accessed January 25 2012.

    • Search Google Scholar
    • Export Citation
  • 83

    SilversteinSBRodgersGM. Parenteral iron therapy options. Am J Hematol2004;76:7478.

  • 84

    ChertowGMMasonPDVaage-NilsenOAhlmenJ. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant2006;21:378382.

    • Search Google Scholar
    • Export Citation
  • 85

    AuerbachMBallardHGlaspyJ. Clinical update: intravenous iron for anaemia. Lancet2007;369:15021504.

  • 86

    LapointeM. Iron supplementation in the intensive care unit: when, how much, and by what route?Crit Care2004;8(Suppl 2):S3741.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1203 1204 130
PDF Downloads 247 247 26
EPUB Downloads 0 0 0